Microfluidic-based direct identification of virusneutralizing antibodies from comprehensive B-cell repertoires of elite controllers of infection ("μDIVA") for a rapid anti-pandemic response

The innovative microfluidic screening platform μDIVA will allow direct discovery of neutralizing antibodies against viral infections and thus shorten the drug development process. It will be benchmarked with the current pandemic SARS-CoV-2 and applied to the discovery of CMV-neutralizing antibodies.